Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

A population-based gene signature is predictive of breast cancer survival and chemoresponse.

Rathnagiriswaran S, Wan YW, Abraham J, Castranova V, Qian Y, Guo NL.

Int J Oncol. 2010 Mar;36(3):607-16.

2.

Integrated gene expression profile predicts prognosis of breast cancer patients.

Li LF, Xu XJ, Zhao Y, Liu ZB, Shen ZZ, Jin WR, Shao ZM.

Breast Cancer Res Treat. 2009 Jan;113(2):231-7. doi: 10.1007/s10549-008-9925-4. Epub 2008 Feb 16.

PMID:
18278552
3.

Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction.

Wan YW, Sabbagh E, Raese R, Qian Y, Luo D, Denvir J, Vallyathan V, Castranova V, Guo NL.

PLoS One. 2010 Aug 17;5(8):e12222. doi: 10.1371/journal.pone.0012222.

4.

A breast cancer prognostic signature predicts clinical outcomes in multiple tumor types.

Wan YW, Qian Y, Rathnagiriswaran S, Castranova V, Guo NL.

Oncol Rep. 2010 Aug;24(2):489-94.

5.

A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy.

Lin Y, Lin S, Watson M, Trinkaus KM, Kuo S, Naughton MJ, Weilbaecher K, Fleming TP, Aft RL.

Breast Cancer Res Treat. 2010 Oct;123(3):691-9. doi: 10.1007/s10549-009-0664-y. Epub 2009 Dec 6.

6.

Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.

Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, Lyman GH, Nevins JR, Potti A.

JAMA. 2008 Apr 2;299(13):1574-87. doi: 10.1001/jama.299.13.1574. Retraction in: Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, Lyman GH, Nevins JR, Potti A. JAMA. 2012 Feb 1;307(5):453.

PMID:
18387932
7.

Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.

Specht K, Harbeck N, Smida J, Annecke K, Reich U, Naehrig J, Langer R, Mages J, Busch R, Kruse E, Klein-Hitpass L, Schmitt M, Kiechle M, Hoefler H.

Breast Cancer Res Treat. 2009 Nov;118(1):45-56. doi: 10.1007/s10549-008-0207-y. Epub 2008 Oct 17.

PMID:
18925433
8.
9.

Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets.

Martin KJ, Patrick DR, Bissell MJ, Fournier MV.

PLoS One. 2008 Aug 20;3(8):e2994. doi: 10.1371/journal.pone.0002994.

10.

High GINS2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammary cancer stem cells in breast cancer patients.

Zheng M, Zhou Y, Yang X, Tang J, Wei D, Zhang Y, Jiang JL, Chen ZN, Zhu P.

Breast Cancer Res Treat. 2014 Nov;148(2):423-36. doi: 10.1007/s10549-014-3172-7. Epub 2014 Oct 28.

PMID:
25348432
11.

A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer.

Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G, Mauriac L, Katsaros D, Molina F, Theillet C, Darbon JM.

Clin Cancer Res. 2008 Mar 15;14(6):1744-52. doi: 10.1158/1078-0432.CCR-07-1833.

12.
13.

A candidate molecular signature associated with tamoxifen failure in primary breast cancer.

Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.

Breast Cancer Res. 2008;10(5):R88. doi: 10.1186/bcr2158. Epub 2008 Oct 17.

14.

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.

15.

Population-based molecular prognosis of breast cancer by transcriptional profiling.

Ma Y, Qian Y, Wei L, Abraham J, Shi X, Castranova V, Harner EJ, Flynn DC, Guo L.

Clin Cancer Res. 2007 Apr 1;13(7):2014-22.

16.

[Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].

Litviakov NV, Garbukov EIu, Slonimskaia EM, Tsyganov MM, Denisov EV, Vtorushin SV, Khristenko KIu, Zav'ialova MV, Cherdyntseva NV.

Vopr Onkol. 2013;59(3):334-40. Russian.

PMID:
23909034
17.

RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response.

Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, Knudsen KE, Knudsen ES.

Cell Cycle. 2010 Oct 15;9(20):4153-63. Epub 2010 Oct 27.

18.

A potential prognostic long non-coding RNA signature to predict metastasis-free survival of breast cancer patients.

Sun J, Chen X, Wang Z, Guo M, Shi H, Wang X, Cheng L, Zhou M.

Sci Rep. 2015 Nov 9;5:16553. doi: 10.1038/srep16553.

19.

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

Bueno-de-Mesquita JM, van Harten WH, Retel VP, van 't Veer LJ, van Dam FS, Karsenberg K, Douma KF, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJ, Brink G, Floore AN, Glas AM, Roumen RM, Bellot FE, van Krimpen C, Rodenhuis S, van de Vijver MJ, Linn SC.

Lancet Oncol. 2007 Dec;8(12):1079-1087. doi: 10.1016/S1470-2045(07)70346-7. Epub 2007 Nov 26. Erratum in: Lancet Oncol. 2008 Jan;9(1):10.

PMID:
18042430
20.

Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers.

Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Hortobagyi GN, Symmans WF, Uzan S, Andre F, de Thé H, Pusztai L.

Clin Cancer Res. 2011 Apr 15;17(8):2591-601. doi: 10.1158/1078-0432.CCR-10-1045. Epub 2011 Jan 19.

Supplemental Content

Support Center